Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkersfor Pancreatic Neoplasm408 locations incl. BirminghamSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 50 - 75Code: NCT04239573·RecruitingApply to this trial
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])for Lung Non-Small Cell Carcinoma1150 locations incl. AnchorageSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT04267848·Phase 3·RecruitingApply to this trial
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancersfor Metastatic Small Intestinal Adenocarcinoma536 locations incl. AnchorageSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT04205968·Phase 2·RecruitingApply to this trial
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Gliomafor Low Grade AstrocytomaDrug: Selumetinib124 locations incl. AuroraSponsor: National Cancer Institute (NCI)Sex: All·Age: 2 - 21Code: NCT04166409·Phase 3·RecruitingApply to this trial
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyfor B Acute Lymphoblastic Leukemia203 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: 365 Days - 25Code: NCT03959085·Phase 3·RecruitingApply to this trial
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myelomafor Smoldering Plasma Cell MyelomaDrug: Daratumumab741 locations incl. BirminghamSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 18+Code: NCT03937635·Phase 3·RecruitingApply to this trial
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancerfor Previously Treated Non-Small Cell Lung Cancer1229 locations incl. BirminghamSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT03851445·Phase 2, Phase 3·RecruitingApply to this trial
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)for Ganglioneuroblastoma152 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: 365 Days - 30Code: NCT03126916·Phase 3·RecruitingApply to this trial
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Changefor Advanced Lung Non-Small Cell CarcinomaDrug: Osimertinib345 locations incl. AnchorageSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT03191149·Phase 2·RecruitingApply to this trial
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemiafor B Acute Lymphoblastic Leukemia455 locations incl. BirminghamSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18 - 39Code: NCT03150693·Phase 3·RecruitingApply to this trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemiafor Recurrent B Acute Lymphoblastic Leukemia156 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: 1 - 21Code: NCT02981628·Phase 2·RecruitingApply to this trial
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumorsfor Childhood Extracranial Germ Cell Tumor566 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: All agesCode: NCT03067181·Phase 3·RecruitingApply to this trial
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgeryfor Head and Neck Squamous Cell Carcinoma676 locations incl. BirminghamSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 18+Code: NCT02734537·Phase 2·RecruitingApply to this trial
Project: Every Child for Younger Patients With Cancerfor Adrenal Gland Pheochromocytoma245 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 25Code: NCT02402244·RecruitingApply to this trial
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomasfor Intracranial Meningioma780 locations incl. BirminghamSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT02523014·Phase 2·RecruitingApply to this trial